A Friend-ly New Resource for Biomarker Validation?
This article was originally published in Start Up
Executive Summary
Merck is helping one of its top executives launch a new nonprofit venture, called Sage, which will develop disease models and provide an open access platform for researchers to gauge the effects of perturbing them. Pharma has never really supported the diagnostics industry apart from its own internal need for biomarkers. But along with supporting drug development, Sage could actually go to that very kind of diagnostics development that pharma has not wanted to do in the past.
You may also be interested in...
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
The early biotech industry thrived on a combination of hope and hype while diagnostics, which evolved using many of the same tools, was traditionally viewed -- and priced -- almost as a commodity. Now we're seeing the advent of complex, high-value diagnostics. As the techniques underlying tests increase in their biological complexity and the knowledge base of their developers about specific disease areas deepens, is the value proposition becoming more biotech-like?
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
The early biotech industry thrived on a combination of hope and hype while diagnostics, which evolved using many of the same tools, was traditionally viewed -- and priced -- almost as a commodity. Now we're seeing the advent of complex, high-value diagnostics. As the techniques underlying tests increase in their biological complexity and the knowledge base of their developers about specific disease areas deepens, is the value proposition becoming more biotech-like?
BGI Touts Eventual Merck Deal
Beijing Genomics and Merck intend to collaborate, using BGI resources primarily to analyze genomic and epigenetic data off of Merck samples. The announcement was more than just a shot across the bow signaling BGI's intent to dominate the gene sequencing services world. It could eventually extend into the clinical arena, which could open up another whole new collaborative - and competitive - area with the West.